Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadji, Peyman, Aapro, Matti S., Body, Jean-Jacques, Gnant, Michael, Brandi, Maria Luisa, Reginster, Jean Yves, Zillikens, M. Carola, Glüer, Claus-C., de Villiers, Tobie, Baber, Rod, Roodman, G. David, Cooper, Cyrus, Langdahl, Bente, Palacios, Santiago, Kanis, John, Al-Daghri, Nasser, Nogues, Xavier, Eriksen, Erik Fink, Kurth, Andreas, Rizzoli, Rene, Coleman, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384888/
https://www.ncbi.nlm.nih.gov/pubmed/28413771
http://dx.doi.org/10.1016/j.jbo.2017.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384888/
https://www.ncbi.nlm.nih.gov/pubmed/28413771
http://dx.doi.org/10.1016/j.jbo.2017.03.001

Ejemplares similares